Johnson & Johnson reported strong second-quarter results with an 8.5% increase in worldwide sales and significant earnings growth excluding special items. Management's optimistic guidance for 2013, coupled with successful integration of acquisitions and robust performance in the pharmaceutical segment, indicates positive momentum. These factors are likely to boost investor confidence and support a positive short-term impact on the stock price.

[1]